

11-24-00

A

11/22/00

jc966 U.S. PTO

PTO/SB/13/PCT (10-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION		PRIOR APPLICATION EXAMINER	ART UNIT
OCIRS 3.3-060	CLASS	SUBCLASS		
CONT				

jc714 U.S. PTO

09/721047

11/22/00

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR 1.53(b) of pending prior international application Number PCT US99/ 11301, filed on 5/21/99 entitled Transgenic Plants Producing a PAP II Protein which designated the United States.

Note: 37 CFR 1.53(d) cannot be used to file a continuation or divisional application of an international application which has not entered the national stage.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	37 - 20 =	17	x \$18 =	\$ 306.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	6 - 3 =	3	x \$78 =	234.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$ =	
				BASIC FEE (37 CFR 1.16(a))	+ 710.00
				Total of above Calculations =	1,250.00
				Reduction by 50% for filing by small entity (Note 37 CFR 1.27).	
				Total =	1,250.00

- Enclosed are the specification, claims and drawing(s).
- ☐ Applicant claims small entity status. See 37 CFR 1.27.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. 12-1095. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ _____ is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☐ Application Data Sheet is enclosed. See 37 CFR 1.76.
- ☒ Amend the specification by inserting before the first line the sentence: "This application is a ☒ continuation ☐ division of international application number PCT US99/ 11301, filed 5/21/99 (status, abandoned, pending, etc.)."

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

09721047 "112200"

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION

8. ☒ A declaration under 37 CFR 1.63 is enclosed.
9. ☐ Priority of foreign application number _____, filed on _____ in _____
is claimed under 35 U.S.C. 119(a)-(d).
- ☐ The certified copy is enclosed.
10. ☐ A preliminary amendment is enclosed.
11. ☒ Also enclosed: Assignments of Nilgun E. Tumer and Pinger Wang

Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record).

Shawn P. Foley, Esq.

Lerner, David, Littenberg, Krumholz & Mentlik, LLP

600 South Avenue West

Westfield, NJ 07090

Tel.: 908 654-5000

Fax: 908 654-7866

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

11/22/00

Date

Shawn P. Foley

Signature

SHAWN P. FOLEY

Typed or printed name

- ☐ Inventor(s)/Applicant(s)
- ☐ Assignee of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).
- ☒ Attorney or agent of record
- ☐ Filed under 37 CFR 1.34(a)
Registration number if acting under 37 CFR 1.34(a): _____

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

DESCRIPTIONTRANSGENIC PLANTS PRODUCING A PAP II PROTEINGOVERNMENTAL SUPPORT

Work on the invention described herein was supported in part by National
5 Science Foundation Grant MCB 96-31308. Therefore, the Government may have certain
rights in the invention.

TECHNICAL FIELD

This invention relates generally to agricultural biotechnology, and more
specifically to methods and genetic materials for conferring resistance to viruses and/or
10 fungi in plants.

BACKGROUND ART

Many commercially valuable agricultural crops are prone to infection by
plant viruses. These viruses are capable of inflicting significant damage to a crop in a
given season, and thus can drastically reduce its economic value. The reduction in
15 economic value to the farmer in turn results in a higher cost of goods to ultimate
purchasers. Several published studies have been directed to the expression of plant virus
capsid proteins in a plant in an effort to confer resistance to viruses. See, e.g., Abel, *et al.*,
Science 232:738-743 (1986); Cuozzo, *et al.*, *Bio/Technology* 6:549-557 (1988);
Hemenway, *et al.*, *EMBO J.* 7:1273-1280 (1988); Stark, *et al.*, *Bio/Technology* 7:1257-
20 1262 (1989); and Lawson, *et al.*, *Bio/Technology* 8:127-134 (1990). The transgenic
plants exhibited resistance only to the homologous virus and related viruses, however, and
not to unrelated viruses. Kawchuk, *et al.*, *Mol. Plant-Microbe Interactions* 3(5):301-307
(1990), disclose the expression of wild-type potato leafroll virus (PLRV) coat protein gene
in potato plants. Although the infected plants exhibited resistance to PLRV, all of the
25 transgenic plants that were inoculated with PLRV became infected with the virus and thus
allowed for the continued transmission of the virus such that high levels of resistance
could not be expected. See U.S. Patent 5,304,730.

Lodge, *et al.*, *Proc. Natl. Acad. Sci. USA* 90:7089-7093 (1993), report the
Agrobacterium tumefaciens-mediated transformation of tobacco with a cDNA encoding
30 wild-type pokeweed antiviral protein (PAP) and the resistance of the transgenic tobacco

plants to unrelated viruses. PAP is a Type I ribosome-inhibiting protein (RIP) found in the cell walls of *Phytolacca americana* (pokeweed). It is a single polypeptide chain that catalytically removes a specific adenine residue from a highly conserved stem-loop structure in the 28S rRNA of eukaryotic ribosomes, thus interfering with Elongation Factor-2 binding and blocking cellular protein synthesis. See, e.g. Irvin, *et al.*, Pharmac. Ther. 55:279-302 (1992); Endo, *et al.*, Biophys. Res. Comm., 150:1032-1036 (1988); and Hartley, *et al.*, FEBS Lett. 290:65-68 (1991). The observations in *Lodge* are in sharp contrast to previous studies reporting that transgenic plants expressing a viral gene were resistant to that virus and closely related viruses only. See also Beachy, *et al.*, Ann. Rev. Phytopathol. 28:451-474 (1990); and Golemboski, *et al.*, Proc. Natl. Acad. Sci. USA 87:6311-6315 (1990). *Lodge* also reports, however, that the PAP-expressing tobacco plants (i.e., above 10 ng/mg protein) tended to have a stunted, mottled phenotype, and that other transgenic tobacco plants that accumulated the highest levels of PAP were sterile.

Hence, a need remains for a means by which to confer broad spectrum virus resistance to plants which overcomes the problems associated with known methods, and particularly which would require a minimum number of transgenes, the expression of which would not cause plant cell death or sterility.

SUMMARY OF THE INVENTION

A first aspect of the present invention is directed to a recombinant plant cell or part thereof e.g. a protoplast, containing a DNA molecule comprising a sequence encoding a PAP II protein. PAP II proteins include full length, wild-type PAP II, fragments thereof truncated at the C-terminus and other mutants or analogs having at least one amino acid substitution or deletion, but which have an intact catalytic active site amino acid residue E172. The PAP II proteins confer anti-viral and/or anti-fungal properties to plants. DNA molecules comprising sequences encoding the fragments and mutants or analogs, as well as the isolated and purified PAP II proteins *per se*, are also provided.

Another aspect of the present invention is directed to transgenic plants that produce a PAP II protein, and exhibit anti-viral and/or anti-fungal activity. Plant parts e.g., leaves, stems and shoots, containing a DNA molecule comprising a sequence encoding a sequence encoding a PAP II protein, from which whole plants expressing the

DNA can be regenerated, are also provided. Virtually all flowering plants are included. Seed derived from the transgenic plants are also provided.

A further aspect of the present invention is directed to a method for identifying PAP II proteins having substantially no cytotoxicity (e.g., phytotoxicity). The method entails providing a transformed eukaryotic cell transformed with a mutagenized PAP II protein-encoding DNA molecule. The transformed cell is cultured in medium containing an inducer to cause expression of the DNA molecule. The toxicity of the PAP II protein encoded by the DNA is determined by whether the cultured cell survives in the presence of the PAP II protein.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph showing susceptibility of transgenic plants expressing PAP II to *Rhizoctonia solani*; and

Fig. 2 is a bar graph showing salicylic acid levels in transformed *N. Tabacum* cv Samsun plants expressing PAP II and in untransformed plants.

15 BEST MODE OF CARRYING OUT INVENTION

Transgenic plants expressing DNAs encoding a PAP II protein exhibit anti-viral and/or anti-fungal activities with substantially reduced phytotoxicity compared to transgenic plants that produce PAP ("PAP I"). Thus, transgenic plants that express a heterologous PAP II DNA exhibit a normal and fertile phenotype as opposed to the stunted, mottled phenotype characteristic of transgenic plants that produce mature PAP, particularly at relatively high levels (as disclosed in Lodge, *et al.*, Proc. Natl. Acad. Sci. USA 90:7089-7093 (1993)).

By "wild-type PAP," it is meant the PAP amino acid sequence 1-262, the 22-amino acid N-terminal signal peptide ("the N-terminal signal sequence of wild-type PAP"), and the 29 amino acid C-terminal extension (amino acids enumerated 263-291), all illustrated in Table 1 below as SEQ ID NO:2. The corresponding nucleotide sequence is set forth as SEQ ID NO:1. Thus, by the terms "wild-type, mature PAP," or "mature PAP", it is meant the PAP amino acid sequence 1-262 shown in Table 1.

TABLE 1

5'CTATGAAGTCGGGTCAAAGCATATACAGGCTATGCATTGTTAGAAACATTGATGCCTCTGATCC	
CGATAAACAAATACAAATTAGACAATAAGATGACATACAAGTACCTAAACTGTGTATGGGGGAGT	
GAAACCTCAGCTGCTAAAAAAACGTTGTAAGAAAAAAGAAAGTTGTGAGTTAACTACAGGGCG	
5	AAAGTATTGGAAC
AGCTAGTAGGAAGGGAAG ATG AAG TCG ATG CTT GTG GTG ACA ATA TCA ATA	
Met Lys Ser Met Leu Val Val Thr Ile Ser Ile	
(67)	
10	TGG CTC ATT CTT GCA CCA ACT TCA ACT TGG GCT GTG AAT ACA ATC ATC TAC
Trp Leu Ile Leu Ala Pro Thr Ser Thr Trp Ala Val Asn Thr Ile Ile Tyr	
(1)	
(100)	
AAT GTT GGA AGT ACC ACC ATT AGC AAA TAC GCC ACT TTT CTG AAT GAT CTT	
15	Asn Val Gly Ser Thr Thr Ile Ser Lys Tyr Ala Thr Phe Leu Asn Asp Leu
(10) (20)	
CGT AAT GAA GCG AAA GAT CCA AGT TTA AAA TGC TAT GGA ATA CCA ATG CTG	
Arg Asn Glu Ala Lys Asp Pro Ser Leu Lys Cys Tyr Gly Ile Pro Met Leu	
(30) (40)	
20	CCC AAT ACA AAT ACA AAT CCA AAG TAC GTG TTG GTT GAG CTC CAA GGT TCA
Pro Asn Thr Asn Thr Asn Pro Lys Tyr Val Leu Val Glu Leu Gln Gly Ser	
(50)	
AAT AAA AAA ACC ATC ACA CTA ATG CTG AGA CGA AAC AAT TTG TAT GTG ATG	
25	Asn Lys Lys Thr Ile Thr Leu Met Leu Arg Arg Asn Asn Leu Tyr Val Met
(60) (70)	
GGT TAT TCT GAT CCC TTT GAA ACC AAT AAA TGT CGT TAC CAT ATC TTT AAT	
Gly Tyr Ser Asp Pro Phe Glu Thr Asn Lys Cys Arg Tyr His Ile Phe Asn	
(80) (90)	
30	GAT ATC TCA GGT ACT GAA CGC CAA GAT GTA GAG ACT ACT CTT TGC CCA AAT
Asp Ile Ser Gly Thr Glu Arg Gln Asp Val Glu Thr Thr Leu Cys Pro Asn	
(100)	
GCC AAT TCT CGT GTT AGT AAA AAC ATA AAC TTT GAT AGT CGA TAT CCA ACA	
Ala Asn Ser Arg Val Ser Lys Asn Ile Asn Phe Asp Ser Arg Tyr Pro Thr	
35	(110) (120)
TTG GAA TCA AAA GCG GGA GTA AAA TCA AGA AGT CAG GTC CAA CTG GGA ATT	
Leu Glu Ser Lys Ala Gly Val Lys Ser Arg Ser Gln Val Gln Leu Gly Ile	
(130) (140)	
CAA ATA CTC GAC AGT AAT ATT GGA AAG ATT TCT GGA GTG ATG TCA TTC ACT	
40	Gln Ile Leu Asp Ser Asn Ile Gly Lys Ile Ser Gly Val Met Ser Phe Thr
(150)	
GAG AAA ACC GAA GCC GAA TTC CTA TTG GTA GCC ATA CAA ATG GTA TCA GAG	
Glu Lys Thr Glu Ala Glu Phe Leu Leu Val Ala Ile Gln Met Val Ser Glu	
(160) (170)	
45	GCA GCA AGA TTC AAG TAC ATA GAG AAT CAG GTG AAA ACT AAT TTT AAC AGA
Ala Ala Arg Phe Lys Tyr Ile Glu Asn Gln Val Lys Thr Asn Phe Asn Arg	
(180) (190)	
GCA TTC AAC CCT AAT CCC AAA GTA CTT AAT TTG CAA GAG ACA TGG GGT AAG	
Ala Phe Asn Pro Asn Pro Lys Val Leu Asn Leu Gln Glu Thr Trp Gly Lys	
50	(200) (210)
ATT TCA ACA GCA ATT CAT GAT GCC AAG AAT GGA GTT TTA CCC AAA CCT CTC	
Ile Ser Thr Ala Ile His Asp Ala Lys Asn Gly Val Leu Pro Lys Pro Leu	
(220)	

092104-14200

GAG CTA GTG GAT GCC AGT GGT GCC AAG TGG ATA GTG TTG AGA GTG GAT GAA
 Glu Leu Val Asp Ala Ser Gly Ala Lys Trp Ile Val Leu Arg Val Asp Glu
 (230) (240)
 5 ATC AAG CCT GAT GTA GCA CTC TTA AAC TAC GTT GGT GGG AGC TGT CAG ACA
 Ile Lys Pro Asp Val Ala Leu Leu Asn Tyr Val Gly Gly Ser Cys Gln Thr
 (250) (260)
 ACT TAT AAC CAA AAT GCC ATG TTT CCT CAA CTT ATA ATG TCT ACT TAT TAT
 Thr Tyr Asn Gln Asn Ala Met Phe Pro Gln Leu Ile Met Ser Thr Tyr Tyr
 (262) (270)
 10 AAT TAC ATG GTT AAT CTT GGT GAT CTA TTT GAA GGA TTC TGATCATAAACA
 Asn Tyr Met Val Asn Leu Gly Asp Leu Phe Glu Gly Phe (SEQ ID NO:2)
 (280) (290)
 TAATAAGGAGTATATATATATTACTCCAACCTATATTATAAAGCTTAAATAAGAGGCCGTGTTAAT
 TAGTACTTGTTGCCTTTTGCTTTATGGTGTGTTTATTATGCCTTGATGCTTGTAATATTATCTAG
 15 AGAACAAGATGTACTGTGTAATAGTCTTGTGTTGAAATAAACTTCCAATTATGATGCAAAAAAAA
 AAAAAA3' (SEQ ID NO:1)

Table 1 also shows 5' and 3' non-coding, flanking sequences. Upon
 expression in eukaryotic cells, the N-terminal 22-amino acid sequence of wild-type PAP is
 20 co-translationally cleaved, yielding a polypeptide having a molecular weight of about
 32kD, which is then further processed by the cleavage of the C-terminal 29-amino acids
 ("the C-terminal extension of wild-type PAP" or "PAP (263-292)"), yielding mature,
 wild-type PAP (hereinafter "PAP (1-262)") (i.e., that which is isolated from Phytolacca
americana leaves), having a molecular weight of about 29 kD. See Irvin, *et al.*, *Pharmac.*
 25 *Ther.* 55:279-302 (1992); Dore, *et al.*, *Nuc. Acids Res.* 21(18):4200-4205 (1993);
 Monzingo, *et al.*, *J. Mol. Biol.* 233:705-715 (1993); and Tumer, *et al.*, *Proc. Natl. Acad.*
Sci. USA 92:8448-8452 (1995).

The term "PAP-II protein" is meant to include the 310 amino acid
 "immature" wild-type polypeptide disclosed in Poyet, *et al.*, *FEBS letters* 347:268-272
 30 (1994) and the 285-amino acid polypeptide containing amino acid residues 26-310 of the
 immature polypeptide (i.e. "PAP II (1-285)" or "mature PAP II" that excludes the N-
 terminal twenty-five-amino acid signal sequence). The nucleotide sequence and
 corresponding amino acid sequence of wild-type PAP II are set forth in Table 2. They are
 denoted as SEQ ID NOS:3 and 4 respectively.

TABLE 2

PAPII

5 55 ATGAAGATGAAGGTGTTAGAAAGTAGTTGGGTTGGCAATATCGATATGGCTGATGCTTACA
-----+-----+-----+-----+-----+-----+-----114
TACTTCTACTTCCACAATCTTCATCAACCCAACCGTTATAGCTATACCGACTACGAATGT
M K M K V L E V V G L A I S I W L M L T -

10 115 CCACCAGCTTCTTCAAACATAGTGTGTTGACGTTGAGAATGCCACACCAGAAACCTACTCT
-----+-----+-----+-----+-----+-----+-----174
GGTGGTCGAAGAAGTTTGTATCACAACTGCAACTCTTACGGTGTGGTCTTTGGATGAGA
P P A S S N I V F D V E N A T P E T Y S -

15 175 AATTTTCTGACTAGTTTGCAGAGAAGCTGTGAAAGACAAGAAATTGACATGCCATGGAATG
-----+-----+-----+-----+-----+-----+-----234
TTAAAAGACTGATCAAACGCTCTTCGACACTTTCTGTCTTTAACTGTACGGTACCTTAC
N F L T S L R E A V K D K K L T C H G M -

20 235 ATAATGGCCACAACCTCACTGAACAACCCAAGTATGTGTTGGTTGACCTCAAATTCGGA
-----+-----+-----+-----+-----+-----+-----294
TATTACCGGTGTGGGAGTGACTTGTGGGTTTCATACACAACCAACTGGAGTTTAAGCCT
I M A T T L T E Q P K Y V L V D L K F G -

25 295 TCTGGAACATTACATTAGCAATCAGAAGGGGAAACTTATATTTGGAGGGCTATTCTGAC
-----+-----+-----+-----+-----+-----+-----354
AGACCTTGTAAGTGTAATCGTTAGTCTTCCCTTTGAATATAAACCTCCCGATAAGACTG
S G T F T L A I R R G N L Y L E G Y S D -

30 355 ATTTACAATGGAAAATGTCGTTATCGGATCTTCAAGGATTGAGAATCCGATGCCCAAGAG
-----+-----+-----+-----+-----+-----+-----414
TAAATGTTACCTTTTACAGCAATAGCCTAGAAGTTCCTAAGTCTTAGGCTACGGGTTCTC
I Y N G K C R Y R I F K D S E S D A Q E -

35 415 ACCGTTTGCCCCGGGGACAAAAGCAAGCCTGGCACTCAGAATAATATCCCCTATGAAAAG
-----+-----+-----+-----+-----+-----+-----474
TGGCAAACGGGGCCCTGTTCGTTTCGGACCGTGAGTCTTATTATAGGGGATACTTTTC
T V C P G D K S K P G T Q N N I P Y E K -

40 475 AGTTACAAAGGGATGGAATCAAAGGGTGGGGCTAGAACTAAATTAGGGTTAGGAAAGATA
-----+-----+-----+-----+-----+-----+-----534
TCAATGTTTCCCTACCTTAGTTTCCACCCCGATCTTGATTTAATCCCAATCCTTTCTAT
S Y K G M E S K G G A R T K L G L G K I -

45 535 ACACTCAAGAGTCGAATGGGTAAAATCTACGGCAAGGATGCAACGGATCAGAAGCAGTAT
-----+-----+-----+-----+-----+-----+-----594
TGTGAGTTCTCAGCTTACCCATTTTAGATGCCGTTCTACGTTGCCTAGTCTTCGTCTATA
T L K S R M G K I Y G K D A T D Q K Q Y -

50 55

CAAAAAATGAGGCTGAATTTCTTCTTATAGCCGTTCAAATGGTTACTGAGGCATCAAGG
 595 -----+-----+-----+-----+-----+-----+-----654
 GTTTTTTTTACTCCGACTTAAAGAAGAATATCGGCAAGTTTACCAATGACTCCGTAGTTCC
 5
 Q K N E A E F L L I A V Q M V T E A S R -
 TTCAAATACATTGAGAACAAAGTGAAGGCTAAATTTGATGATGCCAATGGGTATCAGCCA
 655 -----+-----+-----+-----+-----+-----+-----714
 10 AAGTTTATGTAACCTCTGTTTCACTTCCGATTTAAACTACTACGGTTACCCATAGTCGGT
 F K Y I E N K V K A K F D D A N G Y Q P -
 GATCCTAAAGCTATTTCCCTAGAGAAAAATTGGGACAGTGTTCCTAAGGTCATTGCAAAA
 715 -----+-----+-----+-----+-----+-----+-----774
 15 CTAGGATTTGATAAAGGGATCTCTTTTAACCCTGTCACAAAGATTCCAGTAACGTTTT
 D P K A I S L E K N W D S V S K V I A K -
 GTTGGCACCTCCGGTGATAGTACTGTTACTTTACCTGGAGACCTAAAAGATGAGAATAAT
 775 -----+-----+-----+-----+-----+-----+-----834
 20 CAACCGTGGAGGCCACTATCATGACAATGAAATGGACCTCTGGATTTTCTACTCTTATTA
 V G T S G D S T V T L P G D L K D E N N -
 25 AAACCTTGGACTACGGCCACCATGAACGACCTTAAGAACGACATTATGGCACTCCTAACC
 835 -----+-----+-----+-----+-----+-----+-----894
 TTTGGAACCTGATGCCGGTGGTACTTGCTGGAATTCTTGCTGTAATACCGTGAGGATTGG
 30 K P W T T A T M N D L K N D I M A L L T -
 CACGTTACTTGCAAGGTTAAAAGTTCCATGTTCCCTGAAATTATGTCTATTATTATAGG
 895 -----+-----+-----+-----+-----+-----+-----954
 35 GTGCAATGAACGTTCCAATTTTCAAGGTACAAGGGACTTTAATACAGGATAATAATATCC
 H V T C K V K S S M F P E I M S Y Y Y R -
 ACTAGTATTAGTAACCTTGGTGAATTCGAGTGAT
 955 -----+-----+-----+-----+-----+-----988
 40 TGATCATAATCATTGGAACCACTTAAGCTCACTA (SEQ ID NO:3)
 T S I S N L G E F E * - (SEQ ID NO:4)

The term "PAP II protein" is also meant to include mutants or analogs of
 45 the wild-type polypeptide such as fragments (e.g. C-terminal deletions) and amino acid
 substitutions and/or deletions. The non-wild type polypeptides contain the wild-type E172
 amino acid residue (see, Poyet, *et al.*, Biochem. Biophys. Res. Comm. 259:582-587
 (1998)) and substantially retain PAP II properties as described herein. Without intending
 to be bound by any particular theory of operation, Applicants believe that this amino acid
 50 residue is necessary for anti-viral and/or anti-fungal activity. Preferred non-wild type
 PAP II proteins include PAP II (1-285, G72D), PAP II (1-285, L254R), PAP II (1-285,

L254A), PAP II (1-237), PAP II (1-238), PAP II (1-239), PAP II (1-240), PAP II (1-241), PAP II (1-242), PAP II (1-243), PAP II (1-244), PAP II (1-245), PAP II (1-246), PAP II (1-247), PAP II (1-248), PAP II (1-249), PAP II (1-250), PAP II (1-251), PAP II (1-252), PAP II (1-253), PAP II (1-254), PAP II (1-255), PAP II (1-256), PAP II (1-257), PAP II (1-258) and PAP II (1-259). PAP II proteins may be prepared by preparing hosts transformed with the DNAs, culturing the transformed hosts, and isolating the expression product, all in accordance with standard techniques.

Fig. 2 of Poyet, *et al.*, (1998) illustrates that PAP and PAP II amino acid sequences share 33% sequence similarity. Applicants have demonstrated 41% sequence similarity. There is much greater similarity between the active sites of these respective polypeptides, however. That is, the active sites are substantially conserved. Thus, it would have been expected that the cytotoxicity of PAP II was roughly equal to that of PAP, despite the lack of high overall sequence similarity.

PAP II exhibits anti-viral activity. Expression of a PAP II protein in a transgenic plant confers broad spectrum virus resistance, i.e., resistance to or the capability of suppressing infection by a number of unrelated viruses, including but not limited to RNA viruses e.g., potexviruses such as (PVX, potato virus X), potyvirus (PVY), cucumber mosaic virus (CMV), tobacco mosaic viruses (TMV), barley yellow dwarf virus (BYDV), wheat streak mosaic virus, potato leaf roll virus (PLRV), plumpox virus, watermelon mosaic virus, zucchini yellow mosaic virus, papaya ringspot virus, beet western yellow virus, soybean dwarf virus, carrot read leaf virus and DNA plant viruses such as tomato yellow leaf curl virus. See also Lodge, *et al.*, *supra.*, Tomlinson, *et al.*, J. Gen. Virol. 22:225-232 (1974); and Chen, *et al.*, Plant Pathol. 40:612-620 (1991).

PAP II also exhibits anti-fungal activity. PAP II proteins confer broad spectrum fungal resistance to plants. PAP II provides increased resistance to diseases caused by plant fungi, including those caused by *Pythium* (one of the causes of seed rot, seedling damping off and root rot), *Phytophthora* (the cause of late blight of potato and of root rots, and blights of many other plants), *Bremia*, *Peronospora*, *Plasmopara*, *Pseudoperonospora* and *Sclerospora* (causing downy mildews), *Erysiphe graminis* (causing powdery mildew of cereals and grasses), *Verticillium* (causing vascular wilts of

vegetables, flowers, crop plants and trees), *Rhizoctonia* (causing damping off disease of many plants and brown patch disease of turfgrasses), *Fusarium* (causing root rot of bean, dry rot of potatoes), *Cochliobolus* (causing root and foot rot, and also blight of cereals and grasses), *Giberella* (causing seedling blight and foot or stalk rot of corn and small grains),
5 *Gaeumannomyces* (causing the take-all and whiteheads disease of cereals), *Sclerotinia* (causing crown rots and blights of flowers and vegetables and dollar spot disease of turfgrasses), *Puccinia* (causing the stem rust of wheat and other small grains), *Ustilago* (causing corn smut), *Magnaporthae* (causing summer patch of turfgrasses), and *Sclerotium* (causing southern blight of turfgrasses). Other important fungal diseases
10 include those caused by *Cercospora*, *Septoria*, *Mycosphaerella*, *Glomerella*, *Colletotrichum*, *Helminthosporium*, *Alternaria*, *Botrytis*, *Cladosporium* and *Aspergillus*.

Applicants also believe that PAP II proteins confer increased resistance to other plant pests including insects, bacteria and nematodes. Important bacterial diseases to which PAP II imparts increased resistance include those caused by *Pseudomonas*,
15 *Xanthomonas*, *Erwinia*, *Clavibacter* and *Streptomyces*.

DNAs encoding PAP II proteins may be synthesized in accordance with standard techniques. See *Ausubel et al.* (eds.), Vol. 1, Chap. 8 in Current Protocols in Molecular Biology, Wiley, NY (1990). The DNAs may also be prepared via PCR techniques. See PCR Protocols, Innis, *et al.* (eds.), Academic Press, San Diego, CA
20 (1990). The PAP II DNA (e.g., a cDNA) is preferably inserted into a plant transformation vector in the form of an expression cassette containing all of the necessary elements for transformation of plant cells. The expression cassette typically contains, in proper reading frame, a promoter functional in plant cells, a 5' non-translated leader sequence, the mutant PAP DNA, and a 3' non-translated region functional in plants to
25 cause the addition of polyadenylated nucleotides to the 3' end of the RNA sequence. Promoters functional in plant cells may be obtained from a variety of sources such as plants or plant DNA viruses. The selection of a promoter used in expression cassettes will determine the spatial and temporal expression pattern of the construction in the transgenic plant. Selected promoters may have constitutive activity and these include the CaMV 35S
30 promoter, the actin promoter (McElroy, *et al.* Plant Cell 2:163-171 (1990); McElroy, *et*

al. Mol. Gen. Genet. 231:150-160 (1991); Chibbar, *et al.* Plant Cell Rep. 12:506-509 (1993), and the ubiquitin promoter (Binet, *et al.* Plant Science 79:87-94 (1991), Christensen, *et al.* Plant Mol. Biol. 12:619-632 (1989); Taylor, *et al.* Plant Cell Rep. 12:491-495 (1993)). Alternatively, they may be wound-induced (Xu, *et al.*, Plant Mol. Biol. 22:573-588 (1993), Logemann, *et al.*, Plant Cell 1:151-158 (1989), Rohrmeier, *et al.*, Plant Mol. Biol. 22:783-792 (1993), Firek, *et al.* Plant Mol. Biol. 22:129-142 (1993), Warener, *et al.* Plant J. 3:191-201 (1993)) and thus drive the expression of the mutant PAP gene at the sites of wounding or pathogen infection. Other useful promoters are expressed in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example). Patent publication WO 93/07278, for example, describes the isolation of the maize *trpA* gene which is preferentially expressed in pith cells. Hudspeth, *et al.*, Plant Mol. Biol. 12:579-589 (1989), describes a promoter derived from the maize gene encoding phosphoenolpyruvate carboxylase (PEPC) which directs expression in a leaf-specific manner. Alternatively, the selected promoter may drive expression of the gene under a light-induced or other temporally-regulated promoter. A further alternative is that the selected promoter be chemically regulated.

A variety of transcriptional cleavage and polyadenylation sites are available for use in expression cassettes. These are responsible for correct processing (formation) of the 3' end of mRNAs. Appropriate transcriptional cleavage and polyadenylation sites which are known to function in plants include the CaMV 35S cleavage and polyadenylation sites, the *tml* cleavage and polyadenylation sites, the nopaline synthase cleavage and polyadenylation sites, the pea *rbcS* E9 cleavage and polyadenylation sites. These can be used in both monocotyledons and dicotyledons.

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the genes of this invention to increase their expression in transgenic plants. Various intron sequences have been shown to enhance expression, particularly in monocotyledonous cells. For example, the introns of the maize *Adh1* gene have been found to significantly enhance the expression of the wild-type gene under its cognate promoter when introduced into

maize cells. Intron 1 was found to be particularly effective and enhanced expression in fusion constructs with the chloramphenicol acetyltransferase gene (Callis, *et al.*, Genes Develop 1:1183-1200 (1987)). In the same experimental system, the intron from the maize *bronze-1* gene had a similar effect in enhancing expression (Callis, *et al.*, *supra.*).

- 5 Intron sequences have been routinely incorporated into plant transformation vectors, typically within the non-translated leader.

A number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells. Specifically, leader sequences from Tobacco Mosaic Virus (TMV, the " Ω -sequence"),
10 Maize Chlorotic mottle Virus (MCMV), and Alfalfa Mosaic Virus (AMV) have been shown to be effective in enhancing expression (e.g. Gallie, *et al.* Nucl. Acids Res. 15:8693-8711 (1987); Skuzeski, *et al.* Plant Mol. Biol. 15:65-79 (1990)).

Numerous transformation vectors are available for plant transformation, and the genes of this invention can be used in conjunction with any such vectors. The
15 selection of vector for use will depend upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers may be preferred. Selection markers used routinely in transformations include the *nptII* gene which confers resistance to kanamycin (Messing, *et al.*, Gene 19:259-268 (1982); Bevan, *et al.*, Nature 304:184-187 (1983)), the *bar* gene
20 which confers resistance to the herbicide phosphinothricin (White, *et al.*, Nucl. Acids Res. 18, 1062 (1990); Spencer, *et al.*, Theor. Appl. Genet. 79:625-631 (1990)), the *hph* gene which confers resistance to the antibiotic hygromycin (Blochinger, *et al.*, Mol. Cell Biol. 4:2929-2931)), and the *dhfr* gene, which confers resistance to methotrexate. Vectors suitable for *Agrobacterium* transformation typically carry at least one T-DNA border
25 sequence. These include vectors such as pBIN19 and pCIB200 (EP 0 332 104).

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences can be utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques
30 which do not rely on *Agrobacterium* include transformation via particle bombardment,

protoplast uptake (e.g. PEG and electroporation) and microinjection. The choice of vector depends largely on the preferred selection for the species being transformed. For example, pCIB3064 is a pUC-derived vector suitable for the direct gene transfer technique in combination with selection by the herbicide basta (or phosphinothricin). It is described
5 in WO 93/07278 and *Koziel, et al.*, *Biotechnology 11*:194-200 (1993).

An expression cassette containing the mutant PAP gene DNA containing the various elements described above may be inserted into a plant transformation vector by standard recombinant DNA methods. Alternatively, some or all of the elements of the expression cassette may be present in the vector, and any remaining elements may be
10 added to the vector as necessary.

Transformation techniques for dicotyledons are well known in the art and include *Agrobacterium*-based techniques and techniques which do not require *Agrobacterium*. Non-*Agrobacterium* techniques involve the uptake of exogenous genetic material directly by protoplasts or cells. This can be accomplished by PEG or
15 electroporation mediated uptake, particle bombardment-mediated delivery or microinjection. Examples of these techniques are described by *Paszowski, et al.*, *EMBO J* 3:2717-2722 (1984), *Potrykis, et al.*, *Mol. Gen. Genet.* 199:169-177 (1985), *Reich, et al.*, *Biotechnology* 4:1001-1004 (1986), and *Klein, et al.*, *Nature* 327:70-73 (1987). In each case the transformed cells are regenerated to whole plants using standard techniques.

Agrobacterium-mediated transformation is a preferred technique for
20 transformation of dicotyledons because of its high efficiency of transformation and its broad utility with many different species. The many crop species which are routinely transformable by *Agrobacterium* include tobacco, tomato, sunflower, cotton, oilseed rape, potato, soybean, alfalfa and poplar (EP 0 317 511 (cotton), EP 0 249 432 (tomato), WO
25 87/07299 (*Brassica*), US 4,795,855 (poplar)). *Agrobacterium* transformation typically involves the transfer of the binary vector carrying the foreign DNA of interest (e.g. pCIB200 or pCIB2001) to an appropriate *Agrobacterium* strain which may depend on the complement of *vir* genes carried by the host *Agrobacterium* strain either on a co-resident plasmid or chromosomally (e.g. strain CIB542 for pCIB200 (*Uknes, et al.*, *Plant Cell*
30 5:159-169 (1993))). The transfer of the recombinant binary vector, to *Agrobacterium* is

accomplished by a triparental mating procedure using *E. coli* carrying the recombinant binary vector, a helper *E. coli* strain which carries a plasmid such as pRK2013 which is able to mobilize the recombinant binary vector to the target *Agrobacterium* strain. Alternatively, the recombinant binary vector can be transferred to *Agrobacterium* by DNA transformation (Höfgen, *et al.*, Nucl. Acids Res. 16, 9877 (1988)).

Transformation of the target plant species by recombinant *Agrobacterium* usually involves co-cultivation of the *Agrobacterium* with explants from the plant and follows protocols known in the art. Transformed tissue is regenerated on selectable medium carrying an antibiotic or herbicide resistance marker present between the binary plasmid T-DNA borders.

Preferred transformation techniques for monocots include direct gene transfer into protoplasts using PEG or electroporation techniques and particle bombardment into callus tissue. Transformation can be undertaken with a single DNA species or multiple DNA species (i.e. co-transformation) and both these techniques are suitable for use with this invention. Co-transformation may have the advantage of avoiding complex vector construction and of generating transgenic plants with unlinked loci for the gene of interest and the selectable marker, enabling the removal of the selectable marker in subsequent generations, should this be regarded desirable. However, a disadvantage of the use of co-transformation is the less than 100% frequency with which separate DNA species are integrated into the genome (Schocher, *et al.*, Biotechnology 4:1093-1096 (1986)).

Published European and International Patent Applications EP O 292 435, EP O 392 225 and WO 93/07278 describe techniques for the preparation of callus and protoplasts of maize, transformation of protoplasts using PEG or electroporation, and the regeneration of maize plants from transformed protoplasts. Gordeon-Kamm, *et al.*, Plant Cell 2:603-618 (1990), and Fromm, *et al.*, Biotechnology 11:194-200 (1993), describe techniques for the transformation of elite inbred lines of maize by particle bombardment.

Transformation of rice can also be undertaken by direct gene transfer techniques utilizing protoplasts or particle bombardment. Protoplast-mediated transformation has been described for *Japonica*-types and *Indica*-types (Zhange, *et al.*,

Plant Cell Rep. 7:739-384 (1988); Shimamoto, *et al.* Nature 338:274-277 (1989); Datta, *et al.* Biotechnology 8:736-740 (1990)). Both types are also routinely transformable using particle bombardment (Christou, *et al.* Biotechnology 9:957-962 (1991)).

European Patent Application EP 0 332 581 described techniques for the generation, transformation and regeneration of Pooideae protoplasts. Furthermore wheat transformation has been described in Vasil, *et al.* (Biotechnology 10:667-674 (1992)) using particle bombardment into cells of type C long-term regenerable callus, and in Vasil, *et al.* (Biotechnology 11:1553-1558 (1993)) and Weeks, *et al.* (Plant Physiol. 102:1077-1084 (1993)) using particle bombardment of immature embryos and immature embryo-derived callus.

Transformation of monocot cells such as Zea mays can be achieved by bringing the monocot cells into contact with a multiplicity of needle-like bodies on which these cells may be impaled, causing a rupture in the cell wall thereby allowing entry of transforming DNA into the cells. See U.S. Patent No. 5,302,523. Transformation techniques applicable to both monocots and dicots are also disclosed in the following U.S. Patents: 5,240,855 (particle gun); 5,204,253 (cold gas shock accelerated microprojectiles); 5,179,022 (biolistic apparatus); 4,743,548 and 5,114,854 (microinjection); and 5,149,655 5,120,657 (accelerated particle mediated transformation); 5,066,587 (gas driven microprojectile accelerator); 5,015,580 (particle-mediated transformation of soy bean plants); 5,013,660 (laser beam-mediated transformation); and 4,849,355 and 4,663,292.

The thus-transformed plant cells or plant tissue are then grown into full plants in accordance with standard techniques. Transgenic seed can be obtained from transgenic flowering plants in accordance with standard techniques. Likewise, non-flowering plants such as potato and sugar beets can be propagated by a variety of known procedures. See, e.g. Newell, *et al.* Plant Cell Rep. 10:30-34 (1991) (disclosing potato transformation by stem culture).

PAP II proteins confer broad spectrum fungus and/or virus resistance to a wide variety of plant types, including monocots (e.g., cereal crops) and dicots. Specific examples include maize, tomato, turfgrass, asparagus, papaya, sunflower, rye, beans, ginger, lotus, bamboo, potato, rice, peanut, barley, malt, wheat, alfalfa, soybean, oat,

eggplant, squash, onion, broccoli, sugarcane, sugar beet, beets, apples, oranges, grapefruit, pear, plum, peach, pineapple, grape, rose, carnation, daisy, tulip, Douglas fir, cedar, white pine, scotch pine, spruce, peas, cotton, flax and coffee. As an alternative to preparing transgenic plants containing an exogenous PAP II gene (or a PAP II transgene),

5 PAP II may be applied directly onto the plants.

Other PAP II proteins that exhibit substantially no cytotoxicity e.g., phytotoxicity can be identified using a selection system in eukaryotic cells as disclosed in U.S. Patents 5,756,322 and 5,880,329 in connection with PAP. In a preferred embodiment, a PAP II DNA molecule, operably linked to an inducible promoter functional

10 in the eukaryotic cell, is randomly mutagenized in accordance with standard techniques. The cell is then transformed with the mutagenized PAP II construct. The thus-transformed cell is then cultured in a suitable medium for a predetermined amount of time, e.g., sufficient to cause some growth of the cells, at which time an inducer is added to the medium to cause expression of the mutagenized DNA molecule. Then an observation is

15 made as to whether the cultured cell survives the induction of the expression of the mutagenized PAP II DNA. Survival indicates that the mutagenesis resulted in the expression of a non-toxic PAP II mutant. The PAP II mutant then can be tested *in vitro* or *in vivo* to determine whether it exhibits PAP II anti-viral and/or anti-fungal activity. Preferred *in vitro* assays include eukaryotic translation systems such as reticulocyte lysate

20 systems wherein the extent of the inhibition of protein synthesis in the system caused by the PAP II mutant is determined. Preferred host cells are yeast cells such as *Saccharomyces cerevisiae*. This method can also be conducted with a plurality of randomly mutagenized PAP II DNAs. The PAP II mutants identified as non-toxic and possessing PAP II anti-viral and/or anti-fungal activity, as determined by subsequent

25 assays, can then be isolated, purified and sequenced in accordance with standard techniques.

In another embodiment, the mutagenesis is performed after the transformation of the eukaryotic cell. The disadvantage with mutagenizing the PAP II DNA after transformation is that the chromosomal DNA of the host can also be

30 mutagenized. To determine whether the mutations of the surviving cells are chromosomal

or plasmid-borne in nature, this embodiment requires the step of replacing the transforming PAP II DNA with wild-type PAP II DNA under the control of an inducible promoter, and growing the cells in the presence of the inducer. Mutants which retain the ability to grow are chromosomal mutants, whereas mutants which fail to grow are plasmid-borne (i.e., PAP II) mutants.

The invention will be further described by reference to the detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

EXAMPLES

Example 1: Cloning of PAP II Gene and Comparative Toxicities of PAP I and PAP II in Transformed Tobacco

PAP was purchased from Calbiochem, PAP II was a generous gift of Dr. James Irvin. Polyclonal antibodies against PAP and PAP II were raised in rabbits. PAP II IgG was purified using a protein A affinity column (Bio-Rad, Hercules, CA). Alkaline-phosphatase (Sigma, St. Louis, MO) was conjugated to PAP II IgG by glutaraldehyde (Harlow, *et al.*, "Immunoblotting". In: *Antibodies: A Laboratory Manual*, pp. 471-510, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988)).

Cloning of PAP II cDNA

Total RNA was isolated from 1 gram of pokeweed leaves using Tri-Reagent (Molecular Research Center, Cincinnati, OH). Poly A+ RNA was isolated using an oligo-dT affinity resin (Stratagene, LaJolla, CA). The cDNA library was constructed from 5 μ g total mRNA with a lambda ZAP-cDNA synthesis kit according to the manufacturer's instructions (Stratagene, LaJolla, CA). The cDNA library, the titer of which was 6.25×10^8 pfu/ μ g, was transferred to nitrocellulose and probed with 8×10^6 cpm of 32 P- labeled oligonucleotide 5'GGGTTGTTTCAGTGAGGGTTGTGGCC3' corresponding to the N-terminal region of PAP II cDNA (Poyet, *et al.*, FEBS Lett 347:268-272 (1994)). Four clones with approximately 1 kb inserts were sequenced using the dideoxy chain termination method.

Plant transformation vector and tobacco transformation

A full-length PAP II cDNA insert in pBluescript SK +/- was digested with *PvuII* at its 5' end and *XhoI* at its 3' end. The *PvuII/XhoI* fragment containing PAPII was cloned into the *SmaI* site of the plant transformation vector pMON977. The resulting
5 plasmid contained the PAPII transgene under the control of the 35S promoter from cauliflower mosaic virus and selectable marker neomycin phosphotransferase (NPTII) under the control of the nopaline synthase promoter. The recombinant vector NT159 was introduced to tobacco (*Nicotiana tabacum* cv. Samsun (NN) by *Agrobacterium*-mediated transformation. Transgenic plants generated were screened by ELISA for expression of
10 NPTII and PAP II. The lines that showed expression of both NPTII and PAP II were self-pollinated and R₁ progeny obtained. Homozygous R₂ progeny were selected by germination of R₁ seeds on MS plates containing 100 µg/ml kanamycin.

Virus resistance tests

R₁ progeny from transgenic lines (six leaf stage) were evaluated for
15 resistance to tobacco mosaic virus (TMV, U1 strain) and potato virus X (PVX). Two leaves of each plant were mechanically inoculated with each virus in 50 mM potassium phosphate buffer (pH 7.5) in the presence of carborundum. The inoculated plants were placed in a growth chamber for symptom development (conditions: 14 hour day length, 60% humidity, temperature 23°C during daytime and 19°C at night). The lesion numbers
20 on inoculated leaves were scored 4 days post inoculation for TMV and 10 days post inoculation for PVX. Four leaf discs from the inoculated leaves were sampled with a cork borer (size 7) and homogenized in 150 µl of cold phosphate-buffered saline (PBS, pH 7.5) containing protease inhibitors (1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 µg/ml antipain and 100 µg/ml PMSF). The homogenate was placed on ice for 10 min, centrifuged at
25 14,000 rpm in a microfuge for 5 minutes and the supernatant containing soluble proteins was used for either western blot or ELISA analysis.

Fungal resistance tests

Fungal cultures (*Rhizoctonia solani*) were incubated in the dark at 30°C for 48 hours on potato dextrose agar plates. Pathogen cultures were homogenized and
30 suspended in sterile water and mixed with sterile soil (5 plates for 3 liters of soil). Four-

week old transgenic and control seedlings were transplanted into the inoculated soil. Transplanted seedlings were kept under plastic domes to maintain humidity. Development of disease symptoms was observed for eighteen days and the seedling mortality rate was calculated.

5 Western blot analysis

Total soluble protein (20 μ g) was separated on a 12.5% acrylamide gel together with a PAP II standard (10 ng). The resolved proteins were transferred to a nitrocellulose membrane using a BioRad trans-blot apparatus. The membrane was blocked in 5% non-fat milk in PBS buffer containing 0.1% tween-20 (PBS-T) for one hour, and
10 then incubated with PAP II antiserum (1:500 dilution) overnight at 4°C. Following washing with PBS-T, the membrane was incubated with horse-radish peroxidase conjugated goat anti-rabbit IgG (1:5000) at room temperature for 1 hour and developed with a "Renaissance" chemiluminescence detection kit (Dupont, Wilmington, DE).

The membrane was stripped by incubation in 8M guanidine hydrochloride
15 at room temperature for 30 min. The membrane was then washed four times (15 min each) with PBS-T buffer, blocked in PBS-T containing 5% non-fat milk for 30 min and probed with monoclonal antibodies against PR1 (1:1000).

ELISA analysis

PVX antigen levels were determined by ELISA as described in Hur, *et al.*,
20 Proc. Natl. Acad. Sci. 92:8448-8452 (1995). An ELISA plate was coated with 1 μ g of PAP II IgG per well, to conduct PAP II ELISA. Soluble protein plant extracts (100 μ l) prepared as described for virus resistance analysis, were added to the plates and the plates were incubated overnight at 4°C. Bound PAP II was detected with alkaline phosphatase-conjugated anti-PAP II IgG (1:1000).

25 Salicylic acid analysis

Leaf tissue (0.3g) was collected from young expanded leaves of 5-week old plants from each transgenic and control tobacco line, homogenized in liquid nitrogen and SA was extracted as described by Yalpani, *et al.*, Phytopathology 83:702-708 (1993). Leaf tissue from four different transgenic and wild type plants was analyzed. Free and

total SA were detected by high-performance liquid chromatography and SA levels were quantified. Yalpani, *et al.*, *supra*.

RESULTS

PAPII cDNA cloning and analysis.

5 A cDNA library was constructed in the lambda ZAP vector using polyA+ RNA from *Phytolacca americana* leaves. The cDNA library was screened with a primer corresponding to the 5' terminal sequence of PAP II. Poyet, *et al.*, FEBS letters 347:268-272 (1994). Four putative clones that hybridized to the oligonucleotide probe were sequenced. All four clones had the same 933 bp coding sequence and were identical to the
10 previously described PAP II cDNA. See Poyet, *et al.*, *supra*. Protein sequence predicted from the nucleotide sequence of the cDNA clone showed that PAP II has an extra 25 amino acids at its N-terminus that are not present in the mature protein (Bjorn, *et al.*, Biochimica et Biophysica Acta. 790:154-63 (1984)). Comparison of the protein sequences of PAP II and PAP indicated that PAP II has only 41% identity to PAP and only 20%
15 identity within the last 80 amino acids at the C-terminus. PAP II has no putative lipoprotein lipid attachment site at its C-terminus as previously described for PAP, Hur, *et al.*, *supra*.

Expression and toxicity of PAPII in transgenic tobacco

The full length PAP II cDNA was inserted into a plant transformation
20 vector under the control of the cauliflower mosaic virus 35S promoter. The resulting vector, NT159 was introduced into *Nicotiana tabaccum* cv. Samsun NN by *Agrobacterium*-mediated transformation. *N. tabacum* transformation frequencies, defined as the number of transgenic plants obtained per initial leaf disk times 100, were only slightly reduced for NT159 (5%) compared to the vector control (7-10%). The
25 transformation frequencies were significantly higher for NT159 containing PAP II (5%) compared to 33617, which contains the wild type PAP (0.7%). Lodge, *et al.*, Proc. Natl. Acad. Sci. 90:7089-7093 (1993). Eight different independently transformed tobacco lines positive for NPTII and PAP II expression by ELISA were obtained. All eight R₀ lines produced viable seeds. PAP II protein expressed in transgenic tobacco had the same
30 electrophoretic mobility as mature PAP II isolated from pokeweed, indicating that PAP II

expressed in transgenic tobacco was processed in a similar fashion as in pokeweed (photograph not shown). The cross-reacting lower molecular weight polypeptide observed in the wild type plant (W.T.) was not consistently observed in other untransformed tobacco plants (photograph not shown).

5 Levels of PAP II expression in the eight independent transgenic lines varied. R₁ progeny plants from line 159-9 expressed high levels of PAP II protein (up to 250 ng/mg protein) by immunoblot analysis, while plants from R₁ progeny of line 159-8 had moderate levels of PAP II expression (20-100 ng/mg protein). A few plants from line 159-9 showed chlorotic lesions on their leaves, as previously observed in transgenic plants
10 expressing PAP and PAP-variant Lodge, *et al.*, *supra*. To determine if the presence of these lesions correlated with the levels of PAP II expression, plants from R₁ progeny of line 159-9 with or without chlorotic lesions were analyzed for expression of PAP II using immunoblot analysis. Individual plants that showed chlorotic lesions expressed higher levels of PAP II (above 150 ng/mg protein) than those that did not have lesions (less than
15 100 ng/mg protein) (photograph not shown). R₁ progeny from line 159-8 expressing 10-80 ng/mg PAP II appeared perfectly normal (photograph not shown). These results indicate that PAP II is expressed at least 10-fold higher levels than wild type PAP in transgenic tobacco plants (Lodge, *et al.*, *supra*). The higher accumulation of PAP II in transgenic tobacco plants and the higher transformation frequencies observed with PAP II
20 containing vectors indicate that PAP II is less toxic to transgenic plants than PAP.

Antiviral activity of transgenic tobacco expressing PAP II

To determine if transgenic tobacco plants expressing PAP II are resistant to viral infection, self-fertilized R₁ progeny from transgenic lines were screened for the presence of PAP II by ELISA, and only PAP II- positive plants were used in the virus
25 resistance tests. R₁ progeny from line 159-9 (159-91), with high levels of PAP II and R₁ progeny from lines 159-8 (159-81 and 159-82), with lower levels were challenged with 0.1 µg/ml TMV and 5 µg/ml PVX. Symptom development on both inoculated and upper leaves was monitored visually each day up to 21 days post inoculation. Plants from line 159-91 with high levels of PAP II (150 ng of PAP II per mg of total protein by ELISA)

were evaluated in the same experiment along with wild type tobacco plants. The results are shown in Table 3.

TABLE 3

Susceptibility of Transgenic Tobacco Plants Expressing PAP II to Infection by TMV and PVX

Lines	PAP II [§] (ng/mg)	<u>TMV #</u>	<u>PVX ¶</u>
		Number of HR Lesion	Number of Lesion
W.t	0	90±29	94±6
159-91	150 ±20	18±20*	10±3*
W.t	0	85±34	93±27
159-81	20±5	30±23*	41±31*
159-82	11±2	34±24*	52±29*

§ Five wild type plants and ten plants from R₁ progeny of each tobacco line were analyzed by ELISA for expression of PAP II. Mean value ± SD are shown, and expressed as ng of PAP II per mg of total plant protein.

Ten transgenic plants (Samsun NN) were inoculated with TMV 0.1 µg/ml. After three days of postinoculation, the numbers of lesions were counted.

¶ Ten plants (Samsun NN) were inoculated with PVX at 5 g/ml. After 12 days, the numbers of local lesions on the inoculated leaves were counted.

* Significantly different from wild type at 1% level.

As shown in Table 3 (upper panel), plants from line 159-91 showed 80% reduction in TMV lesion numbers compared to the control plants. Plants from lines 159-81 and 159-82, with lower levels of PAP II (20 and 11 ng PAP II per mg total protein by ELISA), evaluated in another experiment, showed 65% and 60% reduction in TMV lesion numbers, respectively compared to the control plants (Table 3, lower panel). Similar results were obtained when transgenic plants expressing PAP II were inoculated with potato virus X (PVX) (Table 3). Line 159-91 showed an 89% reduction in PVX lesion

numbers 10 days post inoculation, while lines 159-81 and 159-82 showed 56% and 44% reduction in PVX lesion numbers, respectively. Similarly, a fewer percentage of PAP II expressing plants showed PVX lesions on their upper leaves compared to the control plants.

5 These results demonstrate that all transgenic lines tested had dramatically reduced numbers of TMV and PVX lesions and the level of resistance to viral infection correlated well with PAP II protein levels in transgenic plants.

Anti-fungal activity of transgenic tobacco expressing PAP II

One month after germination, twenty seedlings from homozygous progeny
10 (R₂ generation) of five different independently transformed lines were transplanted into soil inoculated with the pathogenic fungus *Rhizoctonia solani*. Plants were kept under plastic domes throughout the experiment to maintain high relative humidity. Disease progression was monitored for three weeks and the percentage of dead seedlings recorded at six, ten, fourteen, and eighteen days post transplanting. Seedling mortality and disease
15 development are shown in Fig. 1. Two weeks post transplanting, 90% of the control seedlings were dead. All transgenic lines tested were less susceptible to disease. The most resistant lines were 159-91, 159-92 and 159-81. In these lines seedling mortality rate was much less (30% to 40%) compared to the control (90%).

In contrast to the most resistant lines, one transgenic line (159-82) showed a
20 lower level of resistance. Six days after transplanting into fungus infested soil, 50% of control seedlings were dead, compared to only 35% in line 159-82. By two weeks post transplanting, 90% of the control seedlings were dead, compared to 75% in line 159-82. Examination of PAP II levels in the transgenic lines that survived fungal infection showed that PAP II was expressed in each plant (data not shown). Homozygous progeny from
25 lines 159-91 and 159-92, which expressed the highest levels of PAP II, showed the highest levels of resistance. Homozygous progeny from line 159-81 that survived fungal infection, expressed PAP II at similar levels as plants from line 159-92. Homozygous progeny from line 159-82, which expressed the lowest levels of PAP II, showed the lowest level of resistance.

PR expression in transgenic tobacco plants expressing PAP II

It was recently shown that pathogenesis-related proteins (PR-proteins) are induced in transgenic plants expressing PAP. Zoubenko, *et al.*, Nature/Biotechnology 15:992-996 (1997). In many plants including tobacco, the primary infection can trigger an enhanced systemic resistance of the plant to subsequent infection by a variety of pathogens. This nonspecific resistance is known as systemic acquired resistance (SAR) and is associated with the systemic *de novo* synthesis of a large number of PR proteins. To determine if PR protein expression is induced in transgenic plants expressing PAP II, PAP II and PR1 expression were analyzed in R₁ progeny of five different transgenic lines by immunoblot analysis using polyclonal antibodies against PAP II and monoclonal antibodies against PR1. All five transgenic lines expressed PAP II and PR1 (photograph not shown). The level of PR1 expression in transgenic lines correlated well with the levels of PAP II protein (photograph not shown). Lines 159-91, 159-92 and 159-93, which expressed higher levels of PAP II, showed higher levels of PR1 (photograph not shown). Lines 159-81 and 159-82, which expressed lower levels of PAP II, showed lower amounts of PR1 accumulation (photograph not shown). PR1 levels in lines 159-81 and 159-82 were similar to the PR1 levels in wild type plants inoculated with TMV (photograph not shown).

Analysis of salicylic acid levels in transgenic lines expressing PAP II

PR-protein synthesis is induced in response to pathogen attack and correlates well with the induction of SAR that confers nonspecific resistance in the distal parts of plants against different kinds of pathogens. Activation of SAR in plants is closely linked with the induction of salicylic acid (SA) synthesis. To determine if SA levels are elevated in transgenic plants expressing PAP II, free and total SA levels were analyzed in different transgenic lines. As shown in Fig. 2, free SA levels in transgenic plants expressing PAP II were similar to the controls. Similar results were obtained when total SA levels were analyzed (data not shown).

PAP II accumulates in the leaves of pokeweed plants grown in the summer. Unlike PAP, PAP II expression in pokeweed is induced upon environmental stress (unpublished data). PAP II has very low sequence homology to PAP, suggesting that it

may have a different physiological function. The physiological function of RIPs is not known. They are viewed as defense-related proteins because some RIPs such as PAP deadenylate ribosomes from all organisms, and their expression in transgenic plants leads to resistance to viral and fungal infection. See Gornhardt, *et al.*, *Plant J.* 8:97-109 (1995),

5 Lodge, *et al.*, *Proc. Natl. Acad. Sci.* 90:7089-7093 (1993), Logemann, *et al.*, *Bio/Technology* 10:305-308 (1992). Expression of several RIPs is induced by environmental stress. See Reinbothe, *et al.*, *Plant Cell* 6:1197-1209 (1986), Rippmann, *et al.*, *Plant. Mol. Biol.* 35:701-709 (1997), and Stirpe, *et al.*, *FEBS Lett.* 382:309-312 (1996). It has been suggested that these RIPs may regulate protein synthesis during stress.

10 See Gorschen, *et al.*, *Planta* 202:470-478 (1997) and Rippman, *et al.*, *supra*.

PAP II contains a 25 amino acid signal sequence at its N-terminus and like PAP it may also be localized in the cell wall. See Ready, *et al.*, *Proc. Natl. Acad. Sci.* 83:5053-5056 (1986). The results indicate that PAP II is significantly less toxic to transgenic tobacco than PAP in terms of the relative transformation frequencies, phenotype

15 of transgenic plants and the level of transgene expression. Since PAP and PAP II have similar N-glycosylase activity *in vitro*, the differences in their cytotoxicity may not be due to differences in their enzymatic activity. Again, without intending to be bound by any particular theory of operation, the different cytotoxicities of PAP and PAP II may be due to their ability to enter the cytosol. It has been shown that ricin A chain is translocated

20 from the endoplasmic reticulum to the cytosol via a retrograde transport pathway. Rapak, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 24:3783-3788 (1997). It has been previously shown that toxicity of PAP is not due solely to enzymatic activity, but involves specific residues at the N-terminal and C-terminal regions of the protein Hur, *et al.*, *Proc. Natl. Acad. Sci.* 92:8448-8452 (1995). The C-terminal 25 amino acids of PAP appear to be critical for

25 cytotoxicity because deletion of these sequences abolishes toxicity towards yeast and transgenic plants (Hur, *et al.*, *supra*.) PAP and PAP II are only 20% homologous in this region. The low sequence homology at the C-terminal regions of PAP and PAP II suggests that the sequence differences near the C-terminus may account for the differences in their toxicity.

Two phenotypically normal transgenic tobacco lines expressing the PAP_{II} gene were resistant to both viral and fungal infection. The mechanism of antiviral and antifungal activity of ribosome inactivating proteins from pokeweed remains to be elucidated. Based on current data, several models could be proposed. Again, without intending to be found by any particular theory of operation, they are as follows. In one model, PAP and PAP II, localized in the cell wall, enter the cell along with the pathogen and indirectly inhibit pathogen propagation by inactivating host ribosomes, thus killing infected cells. Ready, *et al.*, *supra*. In support of this model, positive correlations were reported between depurination of host ribosomes and antiviral activity of exogenously applied RIPs in tobacco against TMV. Taylor, *et al.*, Plant J. 5:827-835 (1994). Applicants have recently demonstrated, however, that a non-toxic C-terminal truncated PAP mutant which did not have detectable ribosome specific depurination activity *in vivo*, had antiviral activity when expressed in transgenic tobacco, suggesting that antiviral activity of PAP can be dissociated from its toxicity. Tumer, *et al.*, Proc. Natl. Acad. Sci. 94:3866-3871 (1997). PAP and other RIPs have been shown to depurinate RNA and DNA substrates in addition to rRNA. Barbieri, *et al.*, Nucleic Acids Research 25:518-522 (1997). Thus, PAP and PAP II may directly attack a pathogen by affecting viral nucleic acid or by depurinating fungal ribosomes.

Another model or hypothesis is that PAP or PAP II expression activates host defense pathways and lead to broad spectrum resistance to pathogen infection, similar to SAR, which is characterized by activation of a signal transduction pathway and synthesis of a number of defense gene products. Applicants have previously shown that the expression of PR proteins is induced in transgenic plants expressing PAP and nontoxic PAP mutants. Zoubenko, *et al.*, Nature/Biotechnology 15:992-996 (1997). These include chitinases and β -1,3-glucanases with proven lytic activity against fungal cell walls. Thus, it is possible that PAP and PAP II access ribosomes of the pathogen by penetrating the cells of invading hyphae by dual action of the transgenes and the host genes that are induced in transgenic plants.

The results demonstrate that transgenic tobacco plants expressing PAP II constitutively express the pathogenesis-related protein PR1 in the absence of pathogen

infection or hypersensitive response. The level of PR1 produced correlates well with the level of PAP II expression, indicating that defense mechanisms are activated in transgenic plants expressing PAP II. Previously, Applicants argued that pathogen resistance in transgenic plants expressing PAP is not due to classical SAR. The apparent activation of defense responses employs a signal transduction pathway different from that involving salicylic acid. Zoubenko *et al.*, *supra*. This theory is supported further by grafting experiments, in which we showed that transgenic tobacco rootstocks expressing PAP induce resistance to virus infection in both wild type *N. tabacum* NN and nn scions in the absence of elevated SA levels. Smirnov, *et al.*, Plant Physiology 114:1113-1121 (1997). These results suggested that PAP expression generates a signal that can translocate across the graft union and induce nonspecific resistance in wild type plants. Smirnov, *et al.*, *supra*. It appears that PAP II transgenic plants exhibit the same type of pathogen resistance as was reported for PAP transgenic plants.

The results demonstrate that although PR1 is constitutively expressed, SA levels are not elevated in PAP II expressing transgenic plants. This is in sharp contrast with the five to tenfold increase necessary for efficient expression of PR proteins. Yalpani, *et al.*, Phytopathology 83:702-708 (1993). These results suggest that both proteins activate a signal transduction pathway different from that controlling SAR or a downstream regulatory signal. Jordanov, *et al.*, Mol. Cell. Biol. 17:3373-3381 (1997), reports that in mammalian cells, inactivation of translationally active ribosomes by ribotoxic agents, including the ribosome inactivating proteins a-sarcin and ricin A chain, strongly induced the stress-activated signal transduction pathway. In the case of PAP, both pathogen and stress-inducible host genes were activated even in transgenic lines expressing nontoxic PAP mutants. Zoubenko, *et al.*, *supra*. In PAP II transgenic plants, PR1 expression was observed in lines that express low levels of PAP II that are phenotypically normal, suggesting that PR protein expression is not induced due to severe perturbation of plant metabolism. However, the resistance observed in PAP and PAP II transgenic lines, in the absence of visible signs of stress, may not exclude a possible involvement of at least some components of the stress-activated signal transduction pathway.

Example 2: Expression of Various PAP II Mutants in Yeast**Construct for Expression of PAP II in *Saccharomyces cerevisiae***

Plasmid containing the wild PAP II (NT148) was digested with *PvuII* and *XhoI*. Following electrophoresis in low melting agarose gel, the restriction fragments containing the PAP II inserts were purified and ligated to the yeast expression vector TKB175 digested with *SmaI* and *XhoI*. The resulting plasmid NT264, contained the selectable marker TRP and PAP II downstream of the galactose-inducible promoter, *GAL1*.

Site-directed Mutagenesis of PAP II cDNA.

Point mutations were introduced into PAP II by site-directed mutagenesis using a Quick-Change™ Mutagenesis Kit (Stratagene) following the manufacturer's instructions. In each mutagenesis experiment, two complementary primers containing a desired point mutation were designed. The PCR mixture contained 125 ng of each primer, 100 ng plasmid DNA template containing PAP II cDNA(NT264), 0.5 mM dNTP and 3 units of Pfu DNA polymerase. PCR was run for 16 cycles (95°C for 30 sec, 55°C for 1 min and 68°C for 12 min; for two nucleotide mutations, time was extended to 18 min). At the end of PCR, 1 unit of *DpnI* restriction enzyme was added to the PCR products for digestion of the parental methylated plasmid DNA at 37°C for 1 hr. Five microliters of the *DpnI* digested PCR products were used for transformation of Epicurian Coli XL1-Blue Super-Competent cells (Stratagene) and plated on Amp+ LB. Mutagenized plasmids were isolated and the presence of the mutated nucleotide was confirmed by sequencing both strands of PAP II using the Sequenase 2.0 DNA Sequencing Kit (United States Biochemical). The primers for mutagenesis were as follows (wherein the numbering of amino acid as designed according to the mature sequence of PAP II):

NT288 (G72D)
G72DF: TTTGGAGGACTATTCTGAC
G72DR: GTCAGAATAG TCCTCCAAA

NT268 (E172V):
E173F: CCGTTCAAATGGTTACTGTGGCATCAAGGTTC
E173R: GAACCTTGATGCCACAGTAACCATTGACGG

NT266(W238stop):

W238F: AAACCTTAGACTACGGCCAC

W238R: GTGGCCGTAGTCTAAGGTTT

5

NT288(W238R)

W238RF: AAACCTAGGACTACGGCCAC

W238RR: GTGGCCGTAG TCCTAGGTTT

10

NT309(L253A)

L253AF: CGACATTATGGCAGCCCTAACCCACGTTAC

L253AR: GTAACGTGGG TTAGGGCTGC CATAATGTCG

NT280 (L254R)

15

L254RF: CGACATTATGGCACTCCGAACCCACGTTACTTGC

L254RR: GCAAGTAACGTGGGTTCGGAGTGCCATAATGTCG

NT271(K260stop):

K260F: CACGTTACTTGCTAGGTAAAAGTTCCATGTTCC

20

K260R: GGAACATGGAACCTTTAACCTAGCAAGTAACGTG

Toxicity Assay of PAP II and Its Mutants

Five micrograms of plasmid DNA containing wild type PAP II or PAP II mutants were transformed into yeast strain PSY1. One half of the transformation mix was plated onto the TRP-medium containing 2% raffinose and other half onto TRP-medium containing 2% galactose. Growth of the transformed yeast on the plates was monitored, and the number of transformants was recorded.

25

Analysis of PAP II Expression in Yeast

A single colony from the yeast transformation plate was first inoculated into 5 ml of liquid TRP-medium containing 2% raffinose and grown to a density 2×10^6 cells per ml. After harvesting, the cells were washed with water, and re-suspended in 20 ml TRP-medium containing either 2% raffinose or 2% galactose. Yeast cells were pelleted by centrifugation at 3000 rpm for 5 min in a table-top centrifuge. The tubes containing pellets were placed on ice for 5 min and an equal volume of 2 x protein sample buffer containing the protease inhibitor mix (2 μ g/ml Aprotinin, 2 μ g/ml Leupeptin, 2 μ g/ml Antipain, and 100 μ g/ml PMSF, Sambrook, *et al*, *Molecular Cloning, A Laboratory Manual* (1989) and 50 μ l acid-washed glass beads were added. The cells were lysed by

30

35

vortexing the samples twice each for 2 min and kept on ice for 1 min. The lysates were boiled for 3 min and centrifuged for 5 min. Aliquots of samples were analyzed by immunoblot using PAP II antiserum.

Toxicity of Wild Type PAP II Expressed in Yeast

5 The results indicate that PAP II is significantly less toxic than PAP to transgenic tobacco plants. To determine if PAP II is as toxic to yeast as PAP, a full length PAP II cDNA was placed under a galactose-inducible *GAL1* promoter and a PGK1 polyadenylation sequence at the 3' end of a yeast expression vector. The wild type PAP gene was introduced into the same vector as a control (NT209). The recombinant vectors
10 NT264 (PAPII) or NT209 (PAP) with Trp- selection marker were introduced into *Saccharomyces cerevisiae*. All transformants harboring NT264 or NT209 were able to grow on the Trp- plate containing 2% raffinose but not on the Trp- plate containing 2% galactose. Comparison of the growth curves for yeast expressing PAP or PAP II showed that the pattern of growth inhibition by PAP II is similar to that observed with PAP,
15 indicating that PAP II is as toxic as PAP when expressed in yeast. Immunoblot analysis showed that PAP II protein was expressed upon induction with galactose. The size of PAP II expressed in yeast is the same as purified PAP II from pokeweed leaves, indicating that PAP II is processed in yeast as it is in pokeweed.

Effect of Mutation of PAP II on its Toxicity to Yeast

20 Three-dimensional structures of many RIPs are similar but not identical. Sequence analysis of PAP II shows that active-site residues conserved in all RIPs are also conserved in PAP II. It has been shown that a mutation of PAP changing E176 to V at the active site region or changing W238 to a stop codon at the C-terminal region abolished the toxicity of PAP to yeast (Hur, *et al.*, *supra.*). When the C-terminal deletion mutant of
25 PAP was expressed in transgenic tobacco plants, the plants were phenotypically normal and were resistant to viral infection, suggesting that toxicity and antiviral activity could be dissociated.

To further dissect the toxicity mechanism and determine whether these residues important to toxicity of PAP are also important for toxicity of PAP II in yeast,
30 nine mutations of PAP II were made by site-directed mutagenesis. The mutagenized PAP

II genes were placed under a galactose-inducible GAL1 promoter in a yeast expression vector, and the toxicity of PAP II mutants was observed under both induced or uninduced conditions. The results are shown in Table 4.

TABLE 4

Effect of Mutations on Toxicity of PAPII to Yeast

Constructs	Mutations	Toxicity
NT264	Wild type	Yes
NT288	G72D	None
NT268	E172V	None
NT266	W238stop	None
NT289	W238R	Yes
NT309	L253Astop	None
NT280	L254R	None
NT307	L254A	None
NT271	K260stop	None

The N-terminal region of PAP II contains a putative RNA binding region that is critical for recognition of RNA substrate. Two tyrosines plus two upstream arginine residues are conserved in most RIPs. Mutation of Glycine72 to charged aspartic acid abolished toxicity of PAP II to yeast (Table 4). It has been shown Y72 of PAP (Y69 in PAP II) interacts with adenine ring of the RNA substrate. G72D mutation may interrupt the interaction of Y72 with the RNA substrate and make it non-toxic to yeast.

E172 of PAP II is conserved among all RIPs and is a key residue at the active-site. In PAP, mutation of the equivalent residue (E176V) abolishes the toxicity and enzymatic activity of PAP. A similar mutation (E172V) was introduced to PAP II. The results show that E172V mutation abolished the toxicity of PAP II to yeast, indicating that this residue plays an important role in enzymatic activity (Table 4).

Previous studies showed that truncation of C-terminal 25 amino acid renders PAP nontoxic to yeast. Crystallographic data show that most of residues in this region are not directly involved in substrate binding or catalysis. One hypothesis is that

this region might be involved in protein-membrane interaction, which is critical for PAP and PAP II to enter the cytosol. A series of single point mutations and truncations were made in the C-terminal region of PAP II. As in PAP, deletion of the C-terminal region after W238, a residue also conserved in PAP, resulted in a nontoxic phenotype. Without
5 intending to be bound by any particular theory of operation, Applicants believe that the C-terminus of PAP and PAP II have similar functions.

Dileucine motif in many proteins has been shown to be important in protein-protein interactions and in the protein sorting pathway. Applicants have discovered that PAP II and PAP also have dileucine motifs at the C-terminal region, which might be
10 important in sorting of PAP II and PAP. These sequences might be critical in interaction of PAP and PAP II with membranes. The dileucine residues are conserved in almost all RIPs, suggesting functional importance of these two residues. To investigate the function of the dileucine residues in PAP II, L253 was changed to alanine (NT309) and L254 was mutated to a short side chain residue alanine (NT307), or to a positive side chain residue
15 arginine (NT280) or to a stop codon (NT309). The results in Table 4 show that all of these mutations abolished the cytotoxicity of PAP II to yeast, indicating that L253 and L254 are critical for toxicity to yeast and residues between L254 and stop codon are critical for toxicity of PAP II to yeast.

Example 3: Expression of PAP II in Turfgrass

An expression vector was constructed for turfgrass transformation which
20 included the PAP II cDNA downstream of the maize ubiquitin promoter and intron in the plant expression vector NT168. Downstream of the PAP II gene, polyadenylation sequences from the small subunit of ribulose 1,5 biphosphate carboxylase E9 gene were present. Transgenic turfgrass plants were generated using particle bombardment.
25 Southern blot analysis identified several independently transformed lines containing PAP II sequences. Immunoblot analysis indicated very high levels of expression of PAP II protein in transgenic plants. The levels of expression of PAP II were greater than the levels observed with nontoxic PAP mutants. Transgenic plants were indistinguishable from wild type plants in their physical characteristics and appearance, indicating that PAP
30 II expression was not toxic to turfgrass.

PAP II confers broad spectrum resistance to numerous pests. This resistance is provided efficiently in that a minimum number of transgenes is required. PAP II is also substantially non-phytotoxic and non-cytotoxic, and thus provides a distinct and unexpected advantage over the use of wild-type PAP. Transgenic plants that express PAP II gene are substantially more resistant to a variety of pathogens, including viruses, fungi, bacteria, nematodes and insects than comparable plants that do not express PAP II. Thus, higher crop yields will be obtained.

All publications mentioned in this specification are indicative of the level of skill of persons skilled in the art to which this invention pertains. All these publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

Various modifications of the invention described herein will become apparent to those skilled in the art. Such modifications are intended to fall within the scope of the appending claims.

INDUSTRIAL APPLICABILITY

The present invention is useful in the genetic engineering of plants, particularly crop plants that are susceptible to infestation by viruses and fungi. Imparting greater resistance to pests will increase crop yield.

09721047.112200

5 Claims:

1. A recombinant plant cell or part thereof containing a DNA molecule comprising a sequence encoding a PAP II protein.
2. The recombinant plant cell or part thereof of claim 1, wherein said plant cell part is a protoplast.
- 10 3. The recombinant plant cell of claim 1 wherein said sequence is SEQ ID NO:3.
4. The recombinant plant cell of claim 1 wherein said sequence encodes PAP II (1-285).
- 15 5. The recombinant plant cell of claim 1 wherein said sequence encodes a mutant PAP II protein that has intact catalytic active site amino acid residue (E172) and exhibits anti-viral and/or anti-fungal activity.
6. The recombinant plant cell of claim 5 wherein said sequence encodes a PAP II protein which is PAP II (1-285, G72D).
7. The recombinant plant cell of claim 5 wherein said sequence encodes a
20 PAP II protein which is PAP II (1-285, L254R)
8. The recombinant plant cell of claim 5 wherein said sequence encodes a PAP II protein which is PAP II (1-285, L254A).
9. The recombinant plant cell of claim 5 wherein said sequence encodes a PAP II protein which is PAP II (1-237).
- 25 10. The recombinant plant cell of claim 5 wherein said sequence encodes a PAP II protein which is PAP II (1-259).
11. The recombinant plant cell of claim 5 wherein said sequence encodes a PAP II protein selected from the group consisting of PAP II (1-237), PAP II (1-238), PAP II (1-239), PAP II (1-240), PAP II (1-241), PAP II (1-242), PAP II (1-243), PAP II (1-244), PAP II (1-245), PAP II (1-246), PAP II (1-247), PAP II (1-248), PAP II (1-249), PAP II (1-250), PAP II (1-251), PAP II (1-252), PAP II (1-253), PAP II (1-254), PAP II (1-255), PAP II (1-256), PAP II (1-257), PAP II (1-258) and PAP II (1-259).
12. A transgenic plant produced from the protoplast of claim 2.
13. A transgenic plant or part thereof comprising a DNA molecule encoding a
35 PAP II protein that upon expression exhibits anti-viral and/or anti-fungal activity.

002217-112200

- 5 14. The transgenic plant of claim 13 which is a monocot plant.
15. The transgenic plant of claim 14 wherein said monocot plant is a cereal
crop plant.
16. The transgenic plant of claim 13 which is a dicot plant.
17. Seed from the transgenic plant of claim 13.
- 10 18. A DNA molecule comprising a sequence encoding a PAP II protein that
has intact catalytic active site amino acid residue (E172) and exhibits anti-viral and/or anti-
fungal activity.
19. The DNA molecule of claim 18 wherein said sequence encodes a PAP II
protein which is PAP II (1-285, G72D).
- 15 20. The DNA molecule of claim 18 wherein said sequence encodes a PAP II
protein which is PAP II (1-285, L254R)
21. The DNA molecule of claim 18 wherein said sequence encodes a PAP II
protein which is PAP II (1-285, L254A).
22. The DNA molecule of claim 18 wherein said sequence encodes a PAP II
20 protein which is PAP II (1-237).
23. The DNA molecule of claim 18 wherein said sequence encodes a PAP II
protein which is PAP II (1-259).
24. The DNA molecule of claim 18 wherein said sequence encodes a PAP II
protein selected from the group consisting of PAP II (1-237), PAP II (1-238), PAP II (1-239),
25 PAP II (1-240), PAP II (1-241), PAP II (1-242), PAP II (1-243), PAP II (1-244), PAP II (1-245),
PAP II (1-246), PAP II (1-247), PAP II (1-248), PAP II (1-249), PAP II (1-250), PAP II (1-251),
PAP II (1-252), PAP II (1-253), PAP II (1-254), PAP II (1-255), PAP II (1-256), PAP II (1-257),
PAP II (1-258) and PAP II (1-259).
25. An isolated and purified mutant PAP II protein having intact catalytic
30 active site amino acid residue (E172) and exhibits anti-viral and/or anti-fungal activity.
26. The PAP II protein of claim 25 which is PAP II (1-285, G72D).
27. The PAP II protein of claim 25 which is PAP II (1-285, L254R)
28. The PAP II protein of claim 25 which is PAP II (1-285, L254A).
29. The PAP II protein of claim 25 which is PAP II (1-237).
- 35 30. The PAP II protein of claim 25 which is PAP II (1-259).

- 5 31. The PAP II protein of claim 25 which is selected from the group
consisting of PAP II (1-237), PAP II (1-238), PAP II (1-239), PAP II (1-240), PAP II (1-241),
PAP II (1-242), PAP II (1-243), PAP II (1-244), PAP II (1-245), PAP II (1-246), PAP II (1-247),
PAP II (1-248), PAP II (1-249), PAP II (1-250), PAP II (1-251), PAP II (1-252), PAP II (1-253),
PAP II (1-254), PAP II (1-255), PAP II (1-256), PAP II (1-257), PAP II (1-258) and PAP II (1-
10 259).
32. A vector comprising the DNA molecule of claim 25.
33. A method of making a plant that has increased resistance to viruses and/or
fungi, comprising preparing a transgenic plant that expresses a DNA molecule comprising a
sequence encoding a PAP II protein.
- 15 34. The method of claim 33 comprising stably transforming a protoplast with
the DNA molecule, and regenerating the transgenic plant from the transformed protoplast.
35. The method of claim 33 comprising introducing the DNA molecule into a
plant part, and regenerating the transgenic plant from the plant part containing the DNA
molecule.
- 20 36. A method of identifying a PAP II protein having reduced cytotoxicity,
comprising:
- (a) providing a eukaryotic cell stably transformed with a DNA
molecule comprising a sequence encoding a PAP II protein, operably linked to an inducible
promoter functional in said eukaryotic cell;
- 25 (b) culturing the transformed cell in medium;
- (c) adding an inducer to said medium; and
- (d) determining extent of growth of the cultured cell.
37. The method of claim 36 wherein said eukaryotic cell is a yeast cell.

ABSTRACTTRANSGENIC PLANTS PRODUCING A PAP II PROTEIN

Disclosed are recombinant plant cells, plant cell parts, plant parts and transgenic plants containing a DNA molecule comprising a sequence encoding a Pokeweed Antiviral Protein (PAP) II protein. PAP II proteins include full length, wild-type PAP II and substantially nontoxic mutants or analogs including fragments thereof truncated at the C-terminus and other PAP II proteins having an intact catalytic active site amino acid residue E172 but that also have at least one amino acid substitution or deletion, and possess anti-viral and/or anti-fungal activity. DNA molecules comprising sequences encoding the mutants or analogs, as well as the isolated and purified PAP II proteins *per se*, are also disclosed. Methods of identifying nontoxic PAP II mutants are further disclosed.

Transgenic plants that produce a PAP II protein exhibit anti-viral and/or anti-fungal activity. Virtually all flowering plants are included. Seed derived from the transgenic plants are also provided.

15




FIGURE 1




FIGURE 2

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

ATTORNEY'S DOCKET NO.: OCIRS 3.3-060 CONT

As a below-named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Transgenic Plants Producing a PAP II Protein the specification of which

☒ is attached hereto

☐ was filed on _____ as United States Application Number or PCT International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (month, day, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

LISTING OF FOREIGN APPLICATIONS CONTINUED ON PAGE 3 HEREOF ☐ YES ☐ NO

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Application Number: 60/086,374

Filing Date: 5/22/98

Application Number:

Filing Date:

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Parent Application Serial Number:

Parent Filing Date:

Parent Patent No.:

U.S. Parent Application Serial Number:

Parent Filing Date:

Parent Patent No.:

PCT Parent Number: US99/11301

Parent Filing Date: 5/21/99

LISTING OF US APPLICATIONS CONTINUED ON PAGE 3 HEREOF: ☐ YES ☐ NO

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Customer Number 000530

DIRECT ALL CORRESPONDENCE TO: Customer No. 000530

DECLARATION -- Page 2

ATTORNEY DOCKET NO. OCIRS 3.3-060 CONT

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name): Nilgun E. Turner

Inventor's signature Nilgun E. Turner Date 11/21/00

Residence: 50 Red Oak Way, Belle Mead, New Jersey 08502 Citizenship: United States

Mailing Address: 50 Red Oak Way, Belle Mead, New Jersey 08502

Full name of second joint inventor, if any (given name, family name): Pinger Wang

Second Inventor's signature Pinger Wang Date 11/21/00

Residence: Apartment 58, 900 Davidson Road, Piscataway, NJ 08854 Citizenship: CN/US

Mailing Address: Apartment 58, 900 Davidson Road, Piscataway, NJ 08854

Full name of third joint inventor, if any (given name, family name):

Third Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Mailing Address: _____

Full name of fourth joint inventor, if any (given name, family name):

Fourth Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Mailing Address: _____

Full name of fifth joint inventor (given name, family name):

Fifth Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Mailing Address: _____

Full name of sixth joint inventor, if any (given name, family name):

Sixth Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Mailing Address: _____

Full name of seventh joint inventor, if any (given name, family name):

Seventh Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Mailing Address: _____

Full name of eighth joint inventor, if any (given name, family name):

Eighth Inventor's signature _____ Date _____

Residence: _____ Citizenship: _____

Mailing Address: _____

☐ Additional inventors are being named on separately numbered sheets attached hereto.